UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)-- Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson’s disease patients with UCB0599 in the United States of America. UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from the Neuropore-UCB collaboration. Neuropore will receive a $5 million (USD) award as a result of achieving this milestone. “We are pleased to reach the milestone of advancing into Parkinson’s patients for the first time with UCB0599, a therapeutic candidate arising from our collaboration with UCB. We believe that inhibition of alpha-synuclein misfolding and oligomerization with an orally active, brain penetrant, small molecule represents a potential advantage over antibody therapeutics that are currently in development,” stated Errol De Souza, President and CEO of Neuropore Therapies. As announced in Ja
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis SuppurativaPR Newswire
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis [Yahoo! Finance]Yahoo! Finance
- New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial SpondyloarthritisPR Newswire
- Genascence Appoints Jeymi Tambiah as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy [Seeking Alpha]Seeking Alpha